NasdaqGS - Nasdaq Real Time Price USD
Krystal Biotech, Inc. (KRYS)
347.50 +7.29 (+2.14%)
As of 2:20:45 PM EDT. Market Open.
Trade KRYS on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for KRYS
- Previous Close
340.21 - Open
343.59 - Bid 345.30 x 100
- Ask 344.80 x 200
- Day's Range
343.59 - 353.89 - 52 Week Range
130.50 - 356.50 - Volume
212,805 - Avg. Volume
296,011 - Market Cap (intraday)
10.244B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
46.46 - EPS (TTM)
7.48 - Earnings Date (est.) Aug 3, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
339.22
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
KRYS
40.95%
S&P 500 (^GSPC)
7.60%
1-Year Return
KRYS
141.87%
S&P 500 (^GSPC)
20.90%
3-Year Return
KRYS
190.79%
S&P 500 (^GSPC)
69.39%
5-Year Return
KRYS
416.34%
S&P 500 (^GSPC)
72.64%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
10.03B
Enterprise Value
9.22B
Trailing P/E
45.54
Forward P/E
49.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
24.55
Price/Book (mrq)
7.86
Enterprise Value/Revenue
22.08
Enterprise Value/EBITDA
49.71
Financial Highlights
Profitability and Income Statement
Profit Margin
53.93%
Return on Assets (ttm)
9.04%
Return on Equity (ttm)
19.90%
Revenue (ttm)
417.3M
Net Income Avi to Common (ttm)
225.03M
Diluted EPS (ttm)
7.48
Balance Sheet and Cash Flow
Total Cash (mrq)
823.4M
Total Debt/Equity (mrq)
0.71%
Levered Free Cash Flow (ttm)
137.49M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreRaising target price to $356.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $356.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $341.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $341.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $323.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $323.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $333.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $333.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target